SPRY at a glance
ARS Pharmaceuticals, Inc. (SPRY, SEC CIK 1671858) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ARS Pharmaceuticals, Inc. (SPRY) reported revenue of $84.3 million (down 5.5% from FY2024) and a net loss of $171.3 million. Diluted EPS was -$1.74.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding ARS Pharmaceuticals, Inc. (SPRY) shares worth $155.9 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $84.3M
- −5.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $155.9M · +1 vs prior quarter
- Latest 8-K
- Aug 13, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Filing text contains no quarterly revenue, YoY comparison, or profitability percentages
- Filing text contains no segment or product-line performance figures
- Filing text contains no cash position, operating cash flow, or capital deployment figures
- Outlook: neffy commercialization, market acceptance, coverage, regulatory reviews, and cash-flow break-even timing
- Headwinds: competition, reimbursement, third-party dependence, funding needs, trade barriers, and significant operating losses
Risk Factors
- Generic-entry litigation triggered by Lupin and Cipla ANDA filings, with lawsuits filed through April 2026
- No U.S. non-patent exclusivity for neffy, increasing exposure to generic competition
- neffy commercialization concentrated in one approved product, making adoption and reimbursement critical to near-term revenue
- Post-commercialization safety data from a larger patient population could prompt labeling changes or market withdrawal
- Competition from established injectable epinephrine products and emerging intranasal candidates could limit market acceptance
AI summary of the SPRY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, announced August 13, 2026
- Full financial details and management commentary contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $33.7M, including $26.2M neffy product revenue versus $12.8M in Q2 2025
- U.S. neffy market share reached 5%, while field-targeted accounts reached 8% versus 4% in Q2 2025
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Richard Lowenthal resigned from the Board effective July 15, 2026, tied to severance eligibility
- Chief Medical Officer Sarina Tanimoto terminated without cause on July 15, 2026
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Donn Casale appointed CEO effective July 7, 2026, replacing Richard Lowenthal
- Lowenthal terminated without cause, effective immediately, creating leadership-transition risk
AI summaries of SPRY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SPRY
Don't miss the next SPRY filing
- Alerts as it files. A push when SPRY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SPRY, by share count.
- Ask anything. An AI agent that reads every SPRY filing and answers with sources.
SPRY alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Casale Donn | A | Oct 1, 2026 | 1,036,923 | - |
| Smith Margaret Ekins | A | Sep 1, 2026 | 1,001,738 | - |
| Casale Donn | A | Jul 1, 2026 | 898,456 | - |
| Shawver Laura | A | Jun 24, 2026 | 30,000 | - |
| Shah Pratik | A | Jun 24, 2026 | 30,000 | - |
| SCHNEIDER PHILLIP M | A | Jun 24, 2026 | 30,000 | - |
| RA CAPITAL MANAGEMENT, L.P. | A | Jun 24, 2026 | 30,000 | - |
| SAUNDERS BRENT L | A | Jun 24, 2026 | 30,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $89.1M | $84.3M |
| Operating Income | - | -$3.1M | -$179.4M |
| Net Income | -$54.4M | $8.0M | -$171.3M |
| Op. Margin | - | -3.5% | -212.9% |
| Net Margin | - | 9.0% | -203.3% |
| Balance Sheet | |||
| Total Assets | $233.2M | $351.2M | $327.7M |
| Equity | - | $256.8M | $114.3M |
| ROE | - | 3.1% | -149.9% |
| Per Share | |||
| EPS | $-0.57 | $0.08 | $-1.74 |
| Cash Flow | |||
| Operating CF | - | $13.5M | -$170.9M |
| CapEx | $175K | $563K | $339K |
Source: XBRL data in ARS Pharmaceuticals, Inc. (SPRY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SPRY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $155.9M |
| Q1 2026 | 26 | $219.6M |
| Q4 2025 | 23 | $256.0M |
| Q3 2025 | 23 | $205.6M |
| Q2 2025 | 25 | $365.2M |
| Q1 2025 | 22 | $170.5M |
| Q4 2024 | 17 | $137.3M |
| Q3 2024 | 14 | $104.0M |
- BlackRock+299.1K (+6%)
- Bank of America Corp+177.5K (+62%)
- State Street Corp+85.7K (+2%)
- Citigroup+70.6K (+379%)
- Vanguard Portfolio Management LLC+56.3K (+11%)
- Millennium Management−3.58M (-60%)
- Citadel Advisors LLC−1.24M (-70%)
- Goldman Sachs Group−343.4K (-47%)
- Raymond James Financial−206.6K (-39%)
- Morgan Stanley−87.6K (-28%)
- Two Sigma Investments+52.4K
- Principal Financial Group+29.7K
- Allstate+29.6K
- Prudential Financial+10.0K
- Franklin Resources−3.28M
- D.E. Shaw & Co−11.9K
- Fifth Third Bancorp−225
Source: 13F-HR filings on SEC EDGAR (aggregated from 177 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SPRY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| SC 13G | Jul 27, 2026 | - | - | |
| 8-K | Jul 17, 2026 | - | Analysis | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 10-Q | May 15, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 15, 2026 | - | Analysis | |
| 8-K | May 13, 2026 | - | Analysis | |
| SC 13G | Mar 24, 2026 | - | - | |
| 10-K | Mar 9, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SPRY SEC filings: frequently asked questions
Which institutions hold SPRY stock?
As of June 30, 2026, the largest ARS Pharmaceuticals, Inc. (SPRY) holders among the 13F filers tracked by SignalX were BlackRock ($42.5 million), State Street Corp ($29.9 million), Vanguard Capital Management LLC ($20.5 million), Millennium Management ($19.2 million), Third Point LLC ($8.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SPRY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ARS Pharmaceuticals, Inc. (SPRY) reported revenue of $84.3 million (down 5.5% from FY2024) and a net loss of $171.3 million. Diluted EPS was -$1.74. The figures come from the XBRL data in the 10-K.
What did SPRY report in its latest 8-K?
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026, announced August 13, 2026.
What are the latest SPRY SEC filings?
ARS Pharmaceuticals, Inc. (SPRY) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and a Form 4 insider filing on October 5, 2026.
What is SPRY's SEC CIK number?
ARS Pharmaceuticals, Inc. (SPRY)'s SEC Central Index Key (CIK) is 1671858. EDGAR lists every SPRY filing under that number.
Ask anything about SPRY
The research agent reads SPRY's filings, financials, insider trades and 13F holders, then answers with sources.